Status:
ACTIVE_NOT_RECRUITING
Real-life-persistence to Antifibrotic Treatments
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Idiopathic Pulmonary Fibrosis
Eligibility:
All Genders
Brief Summary
This study will help to better understand the persistence rate to antifibrotic (AF) treatment in real life in France and to identify potential areas for improvement by investigating the factors associ...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- All patients with a reimbursement of AF treatment between 2018 and 2022 will be included for analysis.
- Exclusion criteria:
- No exclusion criteria will be applied.
Exclusion
Key Trial Info
Start Date :
October 16 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2025
Estimated Enrollment :
10646 Patients enrolled
Trial Details
Trial ID
NCT06485635
Start Date
October 16 2024
End Date
December 31 2025
Last Update
December 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinityx
Boulogne-Billancourt, France, 92100